TB-219

N/A

Report date: 2024/09/04 17:31:02

Base Information

Drug NameTB-219

Drug Alias NameTB-219

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTherabest INC

China Registration ClassN/A

Develop Information

Active CompaniesTherabest INC

Inactive CompaniesN/A

Active IndicationsLymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A